Nicollet Investment Management Inc. Sells 104 Shares of Johnson & Johnson (NYSE:JNJ)

Nicollet Investment Management Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,666 shares of the company’s stock after selling 104 shares during the quarter. Johnson & Johnson makes up 1.9% of Nicollet Investment Management Inc.’s investment portfolio, making the stock its 16th largest position. Nicollet Investment Management Inc.’s holdings in Johnson & Johnson were worth $3,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Taylor & Morgan Wealth Management LLC raised its stake in Johnson & Johnson by 1.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after buying an additional 57 shares during the last quarter. Circle Wealth Management LLC raised its stake in Johnson & Johnson by 0.5% during the first quarter. Circle Wealth Management LLC now owns 11,326 shares of the company’s stock valued at $2,007,000 after buying an additional 59 shares during the last quarter. Red Wave Investments LLC raised its stake in Johnson & Johnson by 2.0% during the second quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after buying an additional 59 shares during the last quarter. Argus Investors Counsel Inc. raised its stake in Johnson & Johnson by 0.6% during the second quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after buying an additional 61 shares during the last quarter. Finally, Alta Capital Management LLC raised its stake in Johnson & Johnson by 0.4% during the second quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after buying an additional 61 shares during the last quarter. 68.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the business’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the sale, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider William Hait sold 15,000 shares of the business’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total value of $2,573,250.00. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at $13,764,485.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now owns 114,676 shares in the company, valued at $18,864,202. The disclosure for this sale can be found here. Over the last quarter, insiders sold 212,646 shares of company stock valued at $36,791,022. Company insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Credit Suisse Group assumed coverage on Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective for the company. Citigroup reduced their target price on Johnson & Johnson from $201.00 to $198.00 in a report on Wednesday, October 5th. StockNews.com initiated coverage on Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Bank of America reduced their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Finally, Atlantic Securities reduced their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $181.33.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $177.01 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The firm has a market capitalization of $462.79 billion, a P/E ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57. The business has a fifty day moving average of $168.35 and a 200 day moving average of $171.28.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same quarter in the previous year, the company posted $2.60 earnings per share. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson declared that its Board of Directors has approved a stock buyback plan on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.55%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.